Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05881460 · ClinicalTrials.gov registry record · NA
Vibrotactile Coordinated Reset: a Non-invasive Treatment for Parkinson's Disease 2
A NA study of Parkinson Disease, sponsored by Synergic Medical Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05881460: Recruiting NA study of Parkinson Disease, sponsored by Synergic Medical Technologies.
NCT05881460 is a NA study of Parkinson Disease that is actively recruiting participants, run by Synergic Medical Technologies. The registered enrollment target is 30 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05881460, a NA study of Parkinson Disease, is actively recruiting participants, sponsored by Synergic Medical Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor function in people with Parkinson's disease (PD). vCR will be administered with a device called the Vibrotactile (VT) Touch device. vCR can be used in conjunction with medication and is expected to delay the need to increase dopamine medication. It also provides a more flexible alternative to deep brain stimulation (DBS) in that the vCR therapy can be easily stopped or modified to better suit the patients' needs.
Primary Outcome
Difference in MDS-UPDRS Part 3 from baseline to 2 months between active and sham. Range is 0-72 (18 items with 4 being max for each item), higher being worse
Conditions Studied
Interventions
- DEVICE Active vibrotactile coordinated reset
- DEVICE Sham vibrotactile coordinated reset
Study Locations (1)
Oregon
- Oregon Health & Science Institution - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2026-01 |
| Phase | NA |
What NCT05881460 shows while recruiting
NCT05881460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Active vibrotactile coordinated reset is the first listed.
NCT05881460 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05881460 about?
NCT05881460 is a clinical study titled "Vibrotactile Coordinated Reset: a Non-invasive Treatment for Parkinson's Disease 2". The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor function in people with Parkinson's disease (PD). vCR will be administered with a device called the Vibrotactile (VT) Touch device. vCR can be used in conjunction with medication and is ...
What is the current status of trial NCT05881460?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-07-12. Estimated completion is 2026-01.
What conditions does trial NCT05881460 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05881460?
The interventions under investigation include: Active vibrotactile coordinated reset (DEVICE), Sham vibrotactile coordinated reset (DEVICE).
Who is sponsoring clinical trial NCT05881460?
This trial is sponsored by Synergic Medical Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05881460 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05881460's enrollment target sits among peer trials
30 209th of 297 higher than 80 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI